Cariprazine for Bipolar I Depression: Study 1
About this title
Study of the Efficacy of a Fixed-dose Regimen of Cariprazine Compared to Placebo for Treatment of the Depressive Episode in Participants With Bipolar I Disorder
Read the official source — NCT02670538Researchers compared Cariprazine and placebo to find out how the approaches affected depression symptoms in people with bipolarity type I during a depressive episode.
Understand this study
What did researchers investigate?
Researchers compared Cariprazine and placebo to find out how the approaches affected depression symptoms in people with bipolarity type I during a depressive episode.
Who was this study for?
This study was for people with bipolarity. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- Birmingham and 88 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
- Recruitment status
- Completed
- Enrollment listed in the registry
- 493
- Sponsor
- Forest Laboratories
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, Bulgaria, Croatia, ...
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT02670538
- Official title
Show the full official title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Fixed-Dose Clinical Trial Evaluating The Efficacy, Safety And Tolerability Of Cariprazine In Patients With Bipolar I Depression
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
Birmingham, United States · Dothan, United States · Phoenix, United States
70 more locations
- Little Rock, United States
- Anaheim, United States
- Cerritos, United States
- Garden Grove, United States
- Glendale, United States
- Oceanside, United States
- Torrance, United States
- Washington D.C., United States
- Coral Springs, United States
- Hallandale, United States
- Lauderhill, United States
- Miami, United States
- Oakland Park, United States
- Atlanta, United States
- Hoffman Estates, United States
- Libertyville, United States
- Naperville, United States
- Shreveport, United States
- Weymouth, United States
- Creve Coeur, United States
- St Louis, United States
- Cherry Hill, United States
- Marlton, United States
- Brooklyn, United States
- Buffalo, United States
- New York, United States
- Rochester, United States
- Hickory, United States
- Cincinnati, United States
- Mason, United States
- Oklahoma City, United States
- Tulsa, United States
- Media, United States
- Charleston, United States
- Houston, United States
- Wichita Falls, United States
- Bothell, United States
- Burgas, Bulgaria
- Kazanlak, Bulgaria
- Pleven, Bulgaria
- Plovdiv, Bulgaria
- Varna, Bulgaria
- Popovača, Croatia
- Rijeka, Croatia
- Zagreb, Croatia
- San Juan, Puerto Rico
- Bucharest, Romania
- Galati, Romania
- Iași, Romania
- Belgrade, Serbia
- Kragujevac, Serbia
- Niš, Serbia
- Novi Kneževac, Serbia
- Bardejov, Slovakia
- Bratislava, Slovakia
- Liptovský Mikuláš, Slovakia
- Rimavská Sobota, Slovakia
- Rožňava, Slovakia
- Vranov nad Topľou, Slovakia
- Hlevakha, Ukraine
- Ivano-Frankivsk, Ukraine
- Kharkiv, Ukraine
- Kherson, Ukraine
- Komintern, Ukraine
- Lviv, Ukraine
- Odesa, Ukraine
- Smila, Ukraine
- Ternopil, Ukraine
- Uzhhorod, Ukraine
- Vinnytsia, Ukraine
Interested in joining this study?
Questions about this study
What did researchers investigate?
Researchers compared Cariprazine and placebo to find out how the approaches affected depression symptoms in people with bipolarity type I during a depressive episode.
Who is behind this study?
The study sponsor is Forest Laboratories, a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including Cariprazine and Placebo.
Who was this study for?
This study was for people with bipolarity. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
